Separately, the company and its partner, Otsuka Pharmaceutical Co., Ltd., will present two-year follow up data from the Phase 3 head-to-head trial known as DASISION evaluating SPRYCEL?® (dasatinib) vs. Gleevec?® (imatinib mesylate) in the treatment of patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic-phase. Five-year data from the Phase 3 study (-034) that evaluated the safety and efficacy of SPRYCEL in the treatment of Ph+ CML patients with resistance or intolerance to Gleevec will also be presented. Both sets of results will be presented on Friday, June 3.

ERBITUX ?® (cetuximab) will be highlighted in abstracts that span a wide range of investigational uses in solid tumors such as colorectal, lung and head and neck.  On Saturday, June 4, ERBITUX data evaluating the influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer will be featured in an oral presentation. Bristol-Myers Squibb is developing ERBITUX in partnership with Lilly.

IXEMPRA?® (ixabepilone) will be featured in abstracts reporting results in combination regimens with other chemotherapies or targeted agents in different stages of breast cancer and results in different subgroups. 

Other investigational compounds from the Bristol-Myers Squibb oncology portfolio will be presented, including Phase 2 advanced solid tumor data on brivanib, a selective dual inhibitor of FGF and VEGF signaling. On Monday, June 6, Phase 2 brivanib data in advanced soft tissue sarcoma will also be presented.   BMS 754807 (a dual IGF-1R/IR inhibitor) and BMS 833293 (an SMO antagonist) will also be featured at ASCO.

chicago2011.asco/